Cephagenix focuses on identifying and developing new, effective migraine therapies.
Cephagenix has raised $9.3M in total funding. The most recent round was Seed. The last funding was announced in January 2025.
Cephagenix's investors include AbbVie, AdBio partners.
Cephagenix is headquartered in Glostrup, Denmark.
Cephagenix focuses on identifying and developing new, effective migraine therapies.
Cephagenix is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cephagenix — Funding & Investors." VCBacked, January 16, 2025, https://www.vcbacked.co/company/cephagenix. Accessed September 15, 2026.
VCBacked. (2025). Cephagenix — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/cephagenix
{{cite web |title=Cephagenix — Funding & Investors |url=https://www.vcbacked.co/company/cephagenix |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated